CN Patent

CN120457210A — 萤光素酶突变体

Assigned to Kikkoman Corp · Expires 2025-08-08 · 1y expired

What this patent protects

在一实施方式中，本公开的目的在于提供热稳定性得到改善的萤火虫萤光素酶。在一实施方式中，本公开涉及包含SEQ ID NO:1的第252位等所对应位置的氨基酸残基被取代的氨基酸序列的萤火虫萤光素酶的突变体、热稳定性得到改善的萤光素酶突变体、编码该萤光素酶突变体的多核苷酸、该萤光素酶突变体的生产方法。

USPTO Abstract

在一实施方式中，本公开的目的在于提供热稳定性得到改善的萤火虫萤光素酶。在一实施方式中，本公开涉及包含SEQ ID NO:1的第252位等所对应位置的氨基酸残基被取代的氨基酸序列的萤火虫萤光素酶的突变体、热稳定性得到改善的萤光素酶突变体、编码该萤光素酶突变体的多核苷酸、该萤光素酶突变体的生产方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN120457210A
Jurisdiction
CN
Classification
—
Expires
2025-08-08
Drug substance claim
No
Drug product claim
No
Assignee
Kikkoman Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.